© 2002 by Annals of the Rheumatic Diseases
LEADER
Rheumatoid arthritis
Anti-interleukin 1
autoantibodies
Department of Immunology and Rheumatology, Hôpital Edouard Herriot, 69437 Lyon Cedex 03, France
Correspondence to:
Correspondence to:
miossec@univ-lyon1.fr
A natural treatment for rheumatoid arthritis
Keywords: autoantibodies; cytokine; interleukin 1
; rheumatoid arthritis; inflammation
| The first 150 words of the full text of this article appear below. |
Prognostic markers are greatly needed to detect patients with rheumatoid arthritis (RA) at high risk of developing a destructive form of the disease as this may influence the choice of early treatment. Among the cytokines produced by the inflammatory synovium, interleukin 1 (IL1) appears to have a predominant role in joint destruction. Specific regulation of IL1 involves natural mechanisms, including soluble IL1 receptors, IL1 receptor antagonist (IL1ra), and anti-IL antibodies.1,2 Autoantibodies directed against cytokines were first described in 1989 as being mostly of the IgG isotype and binding with high affinity mainly to IL1
.
It is easy to imagine that defects in this natural regulation may contribute to changes in disease incidence and severity. However, definite demonstration of this association needs confirmation from different studies. With reference to the new study published in this issue of the Annals,3 we will focus on the effect of autoantibodies
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
